The peer-reviewed publication details how CardiolRx™ achieved rapid, sustained relief for individuals burdened by high disease activity. Beyond managing acute symptoms, the study recorded a substantial decrease in annual recurrence rates, alongside a safety profile that the company describes as favorable. These clinical outcomes were central to designing the ongoing, double-blind, placebo-controlled MAVERIC trial.

David Elsley, President and CEO of Cardiol Therapeutics, noted that the data offers the medical community a comprehensive look at a potential non-immunosuppressive treatment option. With patient enrollment for the Phase III study now entering its final stages, the company aims to demonstrate that its small-molecule therapy can effectively alter the standard of care for a condition often characterized by debilitating hospitalizations and limited therapeutic choices.